Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders
NCT06274164
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment studies. Biomarkers are measures of what is happening inside the body, shown by the results of laboratory, imaging or other tests.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- RAI1 Gene 17P11.2 Deletion+Duplication
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 1 month to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Baylor College of Medicine
- Last updated on ClinicalTrials.gov
- June 3, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Texas · 1
- Texas Children's Hospital · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.